Abstract
According to recent experience there is an unexpected high prevalence of treatment resistance in hypertension, i.e. an inefficiency of even complex treatment modalities, increasing the need for multi-drug regimens. Mostly, this applies to systolic hypertension which over the years was found to cause at least as much target organ damage as diastolic. In view of the high prevalence of hypertension, such resistance may be a rising concern. This might not only be due to inefficiency of drugs, but also to low blood pressure levels as treatment goals and to increasing patient age with more systolic hypertension. Over the past few years, some new evidence has accumulated that will contribute to a break-down of the complex of treatment resistance into several categories of both primary and secondary hypertension, the most important may be the high frequency of white-coat hypertension, aldosteronism, low-renin hypertension and adiposity. In turn, the new evidence may lead to effective treatment for nearly every patient suffering therapy resistance. Such efficiency is all the more wanted since blood pressures in these patients are often severe and fraught with serious complications.
Keywords: Aldosteronism, amiloride, guidelines, low-renin, randomized, refractory, trials
Current Drug Therapy
Title: An Increasing Incidence of Treatment Resistance in Hypertension?
Volume: 1 Issue: 3
Author(s): Ivar K. Eide
Affiliation:
Keywords: Aldosteronism, amiloride, guidelines, low-renin, randomized, refractory, trials
Abstract: According to recent experience there is an unexpected high prevalence of treatment resistance in hypertension, i.e. an inefficiency of even complex treatment modalities, increasing the need for multi-drug regimens. Mostly, this applies to systolic hypertension which over the years was found to cause at least as much target organ damage as diastolic. In view of the high prevalence of hypertension, such resistance may be a rising concern. This might not only be due to inefficiency of drugs, but also to low blood pressure levels as treatment goals and to increasing patient age with more systolic hypertension. Over the past few years, some new evidence has accumulated that will contribute to a break-down of the complex of treatment resistance into several categories of both primary and secondary hypertension, the most important may be the high frequency of white-coat hypertension, aldosteronism, low-renin hypertension and adiposity. In turn, the new evidence may lead to effective treatment for nearly every patient suffering therapy resistance. Such efficiency is all the more wanted since blood pressures in these patients are often severe and fraught with serious complications.
Export Options
About this article
Cite this article as:
Eide K. Ivar, An Increasing Incidence of Treatment Resistance in Hypertension?, Current Drug Therapy 2006; 1 (3) . https://dx.doi.org/10.2174/157488506778194893
DOI https://dx.doi.org/10.2174/157488506778194893 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Status of Hormone Replacement Therapy in Post Menopausal Women
Current Drug Therapy Cardiovascular Proteomics
Current Proteomics Editorial [Hot Topic:Role of Food and Nutritional Factors in Metabolic Syndrome X,Cancer and Cardiovascular Diseases (Guest Editor: Undurti N. Das)]
Current Nutrition & Food Science Clinical Potential of VIP by Modified Pharmaco-kinetics and Delivery Mechanisms
Endocrine, Metabolic & Immune Disorders - Drug Targets Calcium and Vitamin D Supplementation. Myths and Realities with Regard to Cardiovascular Risk
Current Vascular Pharmacology Wet Chemistry Approaches for Synthesis of Gold Nanospheres, Nanorods and Nanostars
Current Nanoscience Dissections of the Thoracic Aorta and Evolving Endovascular Strategies
Current Hypertension Reviews Depression and Cardiovascular Disease: Role of Nitric Oxide
Cardiovascular & Hematological Agents in Medicinal Chemistry Editorial (Thematic Issue: Targeting Inflammation in Cardiovascular Disease)
Medicinal Chemistry Diterpenes: A Therapeutic Promise for Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Interaction Between Genetic Polymorphisms in Renin-Angiotensin System (RAS) and Therapeutic Efficacy of RAS Blockade in IgA Nephropathy
Current Pharmacogenomics Large A-V Fistula: Pathophysiological Consequences and Therapeutic Perspectives
Current Vascular Pharmacology Editorial: Oxidative Stress in Pathophysiological Conditions
Current Vascular Pharmacology Overcoming Resistance to EGFR Inhibitors in NSCLC
Reviews on Recent Clinical Trials Prophylactic Neuroprotection
Current Drug Targets Sorafenib (BAY 43-9006): Review of Clinical Development
Current Clinical Pharmacology Thiazolidinediones Anti-Inflammatory and Anti-Atherosclerotic Effects in Type 2 Diabetes Mellitus
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Editorial [Hot Topic:Translating Clinical Evidence into the Practice of Diabetes Care (Guest Editor: Richard W. Grant Contents)]
Current Diabetes Reviews Current Status of Rho-Associated Kinases (ROCKs) in Coronary Atherosclerosis and Vasospasm
Cardiovascular & Hematological Agents in Medicinal Chemistry Diagnosis and New Approaches in the Therapy of Gestational Diabetes Mellitus
Current Diabetes Reviews